352 related articles for article (PubMed ID: 15295046)
1. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
Holleman A; Cheok MH; den Boer ML; Yang W; Veerman AJ; Kazemier KM; Pei D; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
N Engl J Med; 2004 Aug; 351(6):533-42. PubMed ID: 15295046
[TBL] [Abstract][Full Text] [Related]
2. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.
Lugthart S; Cheok MH; den Boer ML; Yang W; Holleman A; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
Cancer Cell; 2005 Apr; 7(4):375-86. PubMed ID: 15837626
[TBL] [Abstract][Full Text] [Related]
3. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
4. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia.
Schotte D; De Menezes RX; Akbari Moqadam F; Khankahdani LM; Lange-Turenhout E; Chen C; Pieters R; Den Boer ML
Haematologica; 2011 May; 96(5):703-11. PubMed ID: 21242186
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
[TBL] [Abstract][Full Text] [Related]
7. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
8. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
[TBL] [Abstract][Full Text] [Related]
9. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Kaspers GJ; Veerman AJ; Pieters R; Van Zantwijk CH; Smets LA; Van Wering ER; Van Der Does-Van Den Berg A
Blood; 1997 Oct; 90(7):2723-9. PubMed ID: 9326239
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.
Hulleman E; Kazemier KM; Holleman A; VanderWeele DJ; Rudin CM; Broekhuis MJ; Evans WE; Pieters R; Den Boer ML
Blood; 2009 Feb; 113(9):2014-21. PubMed ID: 18978206
[TBL] [Abstract][Full Text] [Related]
11. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
Ramakers-van Woerden NL; Pieters R; Loonen AH; Hubeek I; van Drunen E; Beverloo HB; Slater RM; Harbott J; Seyfarth J; van Wering ER; Hählen K; Schmiegelow K; Janka-Schaub GE; Veerman AJ
Blood; 2000 Aug; 96(3):1094-9. PubMed ID: 10910927
[TBL] [Abstract][Full Text] [Related]
12. Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment.
Mesrian Tanha H; Mojtabavi Naeini M; Rahgozar S; Moafi A; Honardoost MA
Tumour Biol; 2016 Jun; 37(6):7861-72. PubMed ID: 26700663
[TBL] [Abstract][Full Text] [Related]
13. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
[TBL] [Abstract][Full Text] [Related]
14. Treatment of high-risk acute lymphoblastic leukemia with protocols PETHEMA LAL 7/78 and LAL 17/84.
Ortega JJ; Javier G; Olivé T
An Esp Pediatr; 1988 Oct; 29 Suppl 34():72-83. PubMed ID: 3214043
[No Abstract] [Full Text] [Related]
15. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples.
Estes DA; Lovato DM; Khawaja HM; Winter SS; Larson RS
Br J Haematol; 2007 Oct; 139(1):20-30. PubMed ID: 17854304
[TBL] [Abstract][Full Text] [Related]
17. [Twenty years of treating childhood acute lymphoblastic leukemia].
Pérez Martínez A; Alonso Ojembarrena A; Ramírez Orellana M; García Castro J; González-Vicent M; Contra Gómez T; Madero López L; Díaz Pérez MA
An Pediatr (Barc); 2006 Sep; 65(3):198-204. PubMed ID: 16956497
[TBL] [Abstract][Full Text] [Related]
18. The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
Mihal V; Hajduch M; Noskova V; Janostakova A; Safarova M; Orel M; Kouzmina G; Stary J; Blazek B; Pospisilova D
Bull Cancer; 2004 Apr; 91(4):E80-9. PubMed ID: 15562558
[TBL] [Abstract][Full Text] [Related]
19. Building better therapy for children with acute lymphoblastic leukemia.
Carroll WL; Raetz EA
Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
[TBL] [Abstract][Full Text] [Related]
20. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]